CPC Biotech and Multiply Labs develop robotic-compatible aseptic connector to boost cell therapy automation.

CPC Biotech, part of Dover, has partnered with Multiply Labs to create the first aseptic connector designed for robotic operation in cell therapy manufacturing. This innovation aims to accelerate production by enabling automation, reducing contamination risks, and increasing efficiency and scalability. The new connector allows robotic systems to handle tubing more reliably, addressing a key challenge in automating cell therapy processes. This collaboration supports faster, more affordable access to advanced therapies for patients.